AnaptysBio Reports P-III Trial (GEMINI-1) Results Of Imsidolimab (Il-36r) for Generalized Pustular Psoriasis
Shots:
- The P-III trial evaluating imsidolimab (IL-36R mAb) vs PBO in 45 patients with GPP flares. The trial met its 1EPs & achieved rapid clearance of pustulation, erythema & scaling through 4wk. after a single dose of imsidolimab (750mg, IV)
- 53.3% vs 13.3% achieved GPPPGA 0/1 (clear or almost clear) at 4wk. who received a single dose of imsidolimab, 66.7% of PBO patients exited (GEMINI-1) early, crossed over to (GEMINI-2) & were eligible to receive rescue therapy with a favorable safety & tolerability profile with no SAEs or sev. AEs, 3.3% had detectable anti-drug Abs which were non-neutralizing
- The company plans to present comprehensive data from (GEMINI-1) and top-line (GEMINI-2) results at a medical meeting in H2’24 along with planning to file the BLA with the US FDA in Q3’24
Ref: AnaptysBio | Image: AnaptysBio
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
